 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ||| dilanubicel (DVX101) / Deverra Therapeutics
Enrollment change, Trial completion date, Trial primary completion date: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 18, 2024
P2, N=35, Recruiting, Sponsor: Fred Hutchinson Cancer Center
N=20 --> 35 | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Mar 2025
- dilanubicel (DVX101) / Deverra Therapeutics
Dilanubicel, a Non-HLA-Matched Pooled Universal Product, Transforming Single Cord Blood Transplantation Success Rates (Room 6DE (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_1490;
As an allogeneic and off-the-shelf cell therapy that does not require donor-recipient matching, dilanubicel is readily accessible on demand and easily adopted into standard CBT. With a significant follow-up, the observation of no relapses may be related to the infusion of 3rd party donor APCs for presentation of MHC and activation of donor T cell responses.
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial completion date: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 16, 2024
P2, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Center
With a significant follow-up, the observation of no relapses may be related to the infusion of 3rd party donor APCs for presentation of MHC and activation of donor T cell responses. Trial completion date: Jun 2026 --> Oct 2026
- || DVX201 / Coeptis
Trial completion, Enrollment change, Trial primary completion date: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS (clinicaltrials.gov) - Jul 18, 2024
P1, N=8, Completed, Sponsor: Coeptis Therapeutics
Trial completion date: Jun 2026 --> Oct 2026 Recruiting --> Completed | N=18 --> 8 | Trial primary completion date: Jun 2024 --> Oct 2023
- | dilanubicel (DVX101) / Deverra Therapeutics
Enrollment change, Trial termination: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov) - Jun 6, 2024
P2, N=1, Terminated, Sponsor: Fred Hutchinson Cancer Center
The study was originally intended to be multi-site but was only conducted at the lead site. Due to the rarity of the subject population & smaller # of enrolling sites, we were not able to reach accrual goals.
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov) - Apr 22, 2024
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Due to the rarity of the subject population & smaller # of enrolling sites, we were not able to reach accrual goals. Trial primary completion date: Dec 2024 --> Jun 2024
- || DVX201 / Coeptis
Trial completion, Enrollment change: Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19 (clinicaltrials.gov) - Mar 15, 2024
P1, N=12, Completed, Sponsor: Deverra Therapeutics, Inc.
Trial primary completion date: Dec 2024 --> Jun 2024 Recruiting --> Completed | N=18 --> 12
- | DVX201 / Coeptis
Trial completion date, Trial primary completion date: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS (clinicaltrials.gov) - Mar 14, 2024
P1, N=18, Recruiting, Sponsor: Deverra Therapeutics, Inc.
Recruiting --> Completed | N=18 --> 12 Trial completion date: Jun 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Jun 2024
- ||| dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open, Enrollment change: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 26, 2024
P2, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Jun 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Jun 2024 Suspended --> Recruiting | N=15 --> 20
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov) - Dec 1, 2023
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Suspended --> Recruiting | N=15 --> 20 Trial primary completion date: Nov 2022 --> Dec 2024
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial completion date, Trial primary completion date: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 7, 2023
P2, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial primary completion date: Nov 2022 --> Dec 2024 Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Oct 2024
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial completion date, Trial primary completion date: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 6, 2023
P2, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Oct 2024 Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Jun 2023 --> Oct 2023
- || dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Apr 4, 2022
P2, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Jun 2023 --> Oct 2023 Not yet recruiting --> Recruiting
- || DVX201 / Coeptis
Enrollment open: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS (clinicaltrials.gov) - Jan 6, 2022
P1, N=18, Recruiting, Sponsor: Deverra Therapeutics, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || DVX201 / Coeptis
Trial initiation date: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS (clinicaltrials.gov) - Oct 3, 2021
P1, N=18, Not yet recruiting, Sponsor: Deverra Therapeutics, Inc.
Not yet recruiting --> Recruiting Initiation date: Sep 2021 --> Dec 2021
- || DVX201 / Coeptis
Enrollment open: Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19 (clinicaltrials.gov) - Aug 10, 2021
P1, N=18, Recruiting, Sponsor: Deverra Therapeutics, Inc.
Initiation date: Sep 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- ||| dilanubicel (DVX101) / Deverra Therapeutics
Trial completion: Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 6, 2021
P2, N=163, Completed, Sponsor: Nohla Therapeutics, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | DVX201 / Coeptis
New P1 trial: Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19 (clinicaltrials.gov) - May 25, 2021
P1, N=18, Not yet recruiting, Sponsor: Deverra Therapeutics, Inc.
- | DVX201 / Coeptis
New P1 trial: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS (clinicaltrials.gov) - May 25, 2021
P1, N=18, Not yet recruiting, Sponsor: Deverra Therapeutics, Inc.
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial completion date, Trial primary completion date: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov) - Apr 22, 2021
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial completion date, Trial primary completion date: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Apr 22, 2021
P2, N=15, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Aug 2021 --> Jun 2025 | Trial primary completion date: Jan 2020 --> Jun 2023
- | dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov) - Dec 24, 2020
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial completion date: Aug 2021 --> Jun 2025 | Trial primary completion date: Jan 2020 --> Jun 2023 Not yet recruiting --> Recruiting
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial initiation date: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov) - Mar 4, 2020
P2, N=10, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Initiation date: Mar 2020 --> Dec 2020
- | dilanubicel (DVX101) / Deverra Therapeutics
New P2 trial: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov) - Sep 9, 2019
P2, N=10, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- ||||| dilanubicel (NLA101) / Nohla Therap
Trial termination: LAUNCH: NLA101 in Adults Receiving High Dose Chemotherapy for AML (clinicaltrials.gov) - Jul 5, 2019
P2, N=146, Terminated, Sponsor: Nohla Therapeutics, Inc.
Initiation date: Mar 2020 --> Dec 2020 Active, not recruiting --> Terminated; Development plan under review.
- | dilanubicel (DVX101) / Deverra Therapeutics
Enrollment change, Trial withdrawal: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 13, 2019
P2, N=0, Withdrawn, Sponsor: Nohla Therapeutics, Inc.
Active, not recruiting --> Terminated; Development plan under review. N=15 --> 0 | Suspended --> Withdrawn
- ||| dilanubicel (DVX101) / Deverra Therapeutics
Trial suspension: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Feb 26, 2019
P2, N=15, Suspended, Sponsor: Nohla Therapeutics, Inc.
N=15 --> 0 | Suspended --> Withdrawn Recruiting --> Suspended
- ||| dilanubicel (NLA101) / Nohla Therap
Enrollment closed, Enrollment change: LAUNCH: NLA101 in Adults Receiving High Dose Chemotherapy for AML (clinicaltrials.gov) - Feb 15, 2019
P2, N=146, Active, not recruiting, Sponsor: Nohla Therapeutics, Inc.
Recruiting --> Suspended Recruiting --> Active, not recruiting | N=220 --> 146
- | dilanubicel (DVX101) / Deverra Therapeutics
Phase classification, Enrollment change, Trial termination: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 26, 2018
P1, N=7, Terminated, Sponsor: Nohla Therapeutics, Inc.
Recruiting --> Active, not recruiting | N=220 --> 146 Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated
- | dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Oct 3, 2018
P2, N=15, Recruiting, Sponsor: Nohla Therapeutics, Inc.
Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated Not yet recruiting --> Recruiting | Trial completion date: Mar 2022 --> Aug 2021 | Initiation date: May 2018 --> Oct 2018 | Trial primary completion date: Mar 2022 --> Jan 2020
- | dilanubicel (DVX101) / Deverra Therapeutics
Enrollment closed: Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 12, 2018
P2, N=160, Active, not recruiting, Sponsor: Nohla Therapeutics, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Mar 2022 --> Aug 2021 | Initiation date: May 2018 --> Oct 2018 | Trial primary completion date: Mar 2022 --> Jan 2020 Recruiting --> Active, not recruiting
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 7, 2018
P2, N=160, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2018 --> Oct 2018
- | dilanubicel (NLA101) / Nohla Therap
Enrollment open, Trial initiation date: LAUNCH: NLA101 in Adults Receiving High Dose Chemotherapy for AML (clinicaltrials.gov) - Jan 29, 2018
P2, N=220, Recruiting, Sponsor: Nohla Therapeutics, Inc.
Trial primary completion date: Apr 2018 --> Oct 2018 Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> Jan 2018
- | dilanubicel (DVX101) / Deverra Therapeutics
New P2 trial: NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 16, 2018
P2, N=15, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- | dilanubicel (NLA101) / Nohla Therap
New P2 trial: LAUNCH: NLA101 in Adults Receiving High Dose Chemotherapy for AML (clinicaltrials.gov) - Oct 4, 2017
P2, N=220, Not yet recruiting, Sponsor: Nohla Therapeutics, Inc.
- | dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 2, 2017
P2, N=160, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting | Initiation date: Oct 2017 --> Jan 2018 Trial primary completion date: Oct 2017 --> Apr 2018
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=15, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Oct 2017 --> Apr 2018 Trial primary completion date: Jun 2017 --> Aug 2018
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment closed: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=15, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2017 --> Aug 2018 Recruiting --> Active, not recruiting
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Jun 2017
- dilanubicel (DVX101) / Deverra Therapeutics
Trial completion: Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies (clinicaltrials.gov) - May 23, 2016
P2, N=15, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Completed
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 1, 2016
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Dec 2016
- dilanubicel (NLA101) / Nohla Therap
Trial completion, Enrollment change, Combination therapy: Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 15, 2014
P1, N=29, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: May 2016 --> Dec 2016 Active, not recruiting --> Completed | N=40 --> 29
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=40 --> 29 Trial primary completion date: May 2014 --> May 2016
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment closed: Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 5, 2013
P2, N=15, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: May 2014 --> May 2016 Recruiting --> Active, not recruiting
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open: Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 22, 2013
P2, N=160, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | dilanubicel (DVX101) / Deverra Therapeutics
New P2 trial: Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov) - Sep 19, 2012
P2, N=160, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- dilanubicel (NLA101) / Nohla Therap
Enrollment closed, Combination therapy: Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 3, 2012
P1, N=40, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting